Shehnaaz Suliman has spent a career changing instruments without changing the tune. Medicine gave her a close view of consequence. Development studies gave her a map of systems. Investment banking supplied the grammar of capital. Biotechnology brought those languages into one room, usually with a whiteboard, a dense agenda and more acronyms than any humane civilization should permit. The titles changed - physician, banker, dealmaker, operator, CEO, director, executive chair - but her stated purpose remained remarkably stable: find a way for decisions to matter at a larger scale.
That continuity is easy to miss if you read her résumé from top to bottom. A medical graduate from Cape Town who goes to Oxford, joins Lehman Brothers, moves through Gilead, Genentech and Roche, helps shape a billion-dollar partnership at Theravance, scales Alector and then leads ReCode Therapeutics sounds like someone with several careers. Suliman describes something closer to one long experiment in leverage. Each stop gave her another answer to the same question.
The courage came first
Suliman grew up on the Cape Flats in South Africa. Her parents had lived in District Six, the multiracial Cape Town neighborhood whose residents were forcibly removed after the area was declared for white people under apartheid. She has written that apartheid intruded on every part of life. By high school, she was protesting, facing armored vehicles, being tear-gassed and campaigning for Nelson Mandela's release.
She remembers February 11, 1990 with particular clarity: Mandela appearing on the balcony of Cape Town City Hall and addressing the public after his release. To Suliman, the day offered proof that sustained conviction could move what once appeared immovable. It also left her with an unusually practical definition of courage. Courage was not ornamental. It was what people used when the cost of silence exceeded the cost of standing up.
It was at Oxford that I realised being an advocate could be as powerful as being an activist.Shehnaaz Suliman, Rhodes Scholar magazine
She entered the University of Cape Town Medical School with one of the first larger cohorts of students of color admitted to an institution that apartheid had reserved for white students. The clinical path fit her desire to be useful, but the scale of structural inequality resisted individual fixes. A practitioner could change the course of one day for one person. Suliman began wondering who changed the system around that day.
Oxford and the discovery of advocacy
A South Africa-at-Large Rhodes Scholarship took her to Balliol College in 1997. She chose an MPhil in Development Studies, looking for a way to understand the structural constraints behind public problems. She later earned an MBA with distinction at Oxford's Saïd Business School. The combination was more revealing than tidy: policy explained why systems behave as they do, while business explained how resources and incentives make them move.
Oxford also gave her a cohort. Suliman has repeatedly returned to those relationships in interviews, describing friends who pursued fair trade, disability access and other public missions. The university's most durable lesson, in her telling, arrived through people rather than parchment. Activism could force an issue into view. Advocacy could bring unlikely parties together, write a different agreement and make a change survive contact with institutions.
That realization helps explain the pivot into healthcare banking at Lehman Brothers and Petkevich & Partners. The move could look like a departure from service. Suliman saw a larger operating surface. Deals decide which companies gain resources, which programs advance and which ideas find partners. Finance was not the mission; it was another instrument capable of changing reach.
A deal can be a form of design
At Gilead Sciences from 2005 to 2010, Suliman worked across acquisitions and licensing as the company expanded into new areas. One project remained especially meaningful to her: partnerships that allowed generic manufacturers to produce lower-cost versions of medicines for resource-limited countries. In a Rhodes interview, she recalled the internal skepticism and the outside support. Her explanation for proceeding was strikingly free of corporate embroidery: it was the right thing to do.
The episode captures a recurring feature of her career. Suliman is interested in mechanisms. Conviction matters, but conviction with a contract can travel. A moral aim still needs terms, incentives, manufacturing knowledge and partners capable of execution. The poetry of impact is lovely. The spreadsheet has to work by Monday.
At Genentech, she moved from the transaction table toward the development portfolio, overseeing more than 30 early programs across several scientific areas. Roche then put her in charge of global partnering for a group of therapeutic areas. The education continued: a promising molecule is only the beginning. A program also needs evidence, sequencing, judgment and the willingness to stop when the case no longer holds. Portfolio leadership is partly the art of loving the mission without becoming sentimental about every project.
Theravance Biopharma brought another large mechanism. As senior vice president of corporate development and strategy, Suliman helped deliver a $1 billion profit-sharing partnership with Janssen around a lead program. At Alector, where she became president and chief operating officer, the work broadened again to scaling a public company, raising capital and advancing a late-stage pipeline. By then she could read a biotechnology company from several seats: clinician, financier, partner, portfolio leader and operator.
Leading the delivery company
Suliman joined ReCode Therapeutics as president and CEO in January 2022. The company's central technology, called SORT, uses lipid nanoparticles engineered to carry genetic medicines to selected organs, tissues and cells. Delivery is the quiet problem beneath many ambitious ideas in genetic medicine: the cargo may be clever, but it is useful only if it reaches the right place. For an executive fascinated by leverage, a delivery platform was an apt assignment. One enabling system could support many different programs and partnerships.
Her mandate combined the disciplines she had collected: advance internal programs, make portfolio choices, raise capital, form collaborations and turn a platform story into clinical work. ReCode reported $370 million raised by 2024. Suliman also added experienced scientific advisers, including biochemist Katalin Karikó and physician-scientist Andrew Bellinger. The appointments illustrated her familiar preference for networks that add real capability, not merely decorative names.
The experience afforded by the Scholarship proved to be a great amplifier.Shehnaaz Suliman, on carrying Oxford into her work
In August 2026, ReCode announced a leadership transition effective July 1: Heather Clark became CEO and Suliman became executive chair. The official language is less cinematic than a founder myth and more useful. She would continue to provide strategic and operational guidance while Clark led the next phase. Good stewardship sometimes means taking the chief executive seat. It can also mean knowing when a different leader's experience fits the company's immediate task.
Build the room, then fill the square
Suliman's idea of scale is not confined to products and financing. She serves on the boards of 10x Genomics and Ultragenyx, has chaired Executive Women in Bio's Boardroom Ready program and has mentored rising leaders. Her public case for representation is typically operational. If boards need different perspectives, prepare candidates, develop networks and make appointments possible.
The Biotech CEO Sisterhood made that instinct visible. After the group's 2024 leadership summit, an idea emerged for women leaders and allies to gather in San Francisco's Union Square during the J.P. Morgan Healthcare Conference. Suliman and colleague Jessica Kelly handled permits and logistics. Four hundred and fifty people arrived in pink in 2025. The Sisterhood reports more than 700 in 2026. A photograph became an annual ritual because somebody did the paperwork. Even solidarity, it turns out, benefits from an operator.
Her pattern is consistent: values become durable when they acquire a mechanism - a license, a portfolio process, a board program, a permit, a successor.
There is warmth alongside the machinery. In an earlier interview, Suliman called herself highly focused and admitted that ambition can knock life out of balance. Asked what she would tell her sixteen-year-old self, she answered, “Remember to enjoy your life as well.” Asked about a month-long sabbatical, she chose exercise, reflection, writing, time with friends and family, and active gratitude. These are modest ambitions, which may be why they feel honest.
Her career offers no neat recipe for moving from protest to the boardroom. It offers something more portable: keep the purpose, expand the toolkit, and resist mistaking a method for an identity. A job title is useful for as long as it gives the work leverage. Then another title may do better. Suliman has spent decades making those changes without pretending they are costless, linear or complete.
The result is a career whose apparent zigzags resolve into a straight question. How can one action reach beyond one room? Sometimes the answer is a medical decision. Sometimes it is a deal, a company, a board seat or hundreds of people in pink occupying a gray financial district. The instrument keeps changing. The tune, stubbornly, does not.